Clinical Trial Update: Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study of guselkumab in skin of color participants with moderate-to-severe plaque psoriasis and/or scalp psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Scalp Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Plaque Psoriasis, Scalp Psoriasis | Phase 3 | Status: COMPLETED